Product image of Melfalan Hikma (Melphalan) supplied by GNH India

Melfalan Hikma

Active Ingredient:
Melphalan
Origin:
EU

Melfalan Hikma (Melphalan)

Melphalan, the active ingredient in Melfalan Hikma, is an alkylating agent presented as an intravenous formulation for intravenous use. It is used in the treatment of certain cancers such as multiple myeloma, ovarian cancer, and malignant melanoma in adult patients.

GNH India supplies Melfalan Hikma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Hikma Farmacêutica (Portugal), S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Melfalan Hikma is an alkylating antineoplastic agent used in the management of specific malignant diseases.

  • Multiple myeloma: helps control disease progression and improve survival in adult patients.
  • Ovarian cancer: used as part of combination chemotherapy to reduce tumor burden.
  • Malignant melanoma: employed in advanced cases to inhibit tumor growth.

How It Works

  • Melphalan acts as an alkylating agent that forms covalent cross‑links between DNA strands, interfering with DNA replication and transcription. These cross‑links prevent cell division and trigger apoptosis in rapidly proliferating cancer cells, thereby reducing tumor mass and disease progression.

Side Effects

Melfalan Hikma may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Nausea and vomiting: gastrointestinal upset commonly reported during treatment.
  • Myelosuppression: decreased blood cell counts leading to anemia, neutropenia, or thrombocytopenia.
  • Fatigue: persistent tiredness affecting daily activities.
  • Alopecia: hair loss that may be temporary or prolonged.
  • Mucositis: inflammation of the mouth and gastrointestinal lining.
  • Diarrhea: loose stools occurring during or after infusion.

Serious or Rare Side Effects

  • Severe infection: due to profound neutropenia, increasing risk of sepsis.
  • Pulmonary toxicity: interstitial pneumonitis or fibrosis presenting with cough and dyspnea.
  • Renal impairment: acute kidney injury manifested by reduced urine output.
  • Secondary malignancies: rare development of new cancers after prolonged exposure.
  • Cardiotoxicity: arrhythmias or myocardial dysfunction in susceptible patients.
  • Hypersensitivity reactions: rash, fever, or anaphylaxis during infusion.

Precautions & Warnings

Before initiating therapy with Melfalan Hikma, several safety considerations should be observed.

  • Baseline blood counts: obtain complete blood count to assess marrow function.
  • Renal function: evaluate serum creatinine and calculate clearance for dose adjustment.
  • Hepatic function: monitor liver enzymes as hepatic impairment may affect metabolism.
  • Pregnancy risk: avoid use in pregnant women; discuss contraception with women of childbearing potential.
  • Infection monitoring: watch for signs of febrile neutropenia and treat promptly.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Avoid Interactions

Melfalan Hikma can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • Live vaccines: concurrent use may cause severe infection due to immunosuppression.
  • High-dose radiation therapy: may increase tissue toxicity and delayed healing.
  • Certain antibiotics (e.g., aminoglycosides): can exacerbate nephrotoxicity.

Moderate Interactions (Monitor Closely)

  • Antifungal agents (azoles): may affect melphalan metabolism and increase toxicity.
  • Allopurinol: can potentiate bone marrow suppression.
  • NSAIDs: may increase risk of renal impairment when combined with melphalan.

Frequently Asked Questions

Melfalan Hikma is an intravenous formulation of melphalan, an alkylating antineoplastic agent indicated for the treatment of multiple myeloma, ovarian cancer, and malignant melanoma in adult patients. It is typically administered as part of a chemotherapy regimen under the supervision of an oncologist.

Melphalan works by forming covalent cross‑links between DNA strands, which blocks DNA replication and transcription. This disruption leads to cell cycle arrest and triggers programmed cell death (apoptosis) in rapidly dividing cancer cells, thereby reducing tumor growth.

The specific dose of Melfalan Hikma is determined by the prescribing oncologist based on the patient’s diagnosis, body surface area, renal function, and treatment protocol. Dosing regimens vary and should be individualized for each patient.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential should use effective contraception. Breastfeeding is not recommended during treatment, as the drug may be excreted in milk and affect the infant.

To order Melfalan Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Melfalan Hikma (melphalan) is a bifunctional alkylating agent similar to cyclophosphamide but is more lipophilic, allowing better cellular uptake. It is often preferred for certain hematologic malignancies like multiple myeloma, whereas other agents may be chosen based on tumor type, toxicity profile, and treatment history.

Melfalan Hikma should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before administration, the product should be inspected for particulate matter and discoloration, and handled using aseptic techniques in a controlled environment.

Melfalan Hikma is given by intravenous infusion, typically over a period of 30‑60 minutes, depending on the prescribed protocol. Administration is performed by qualified healthcare professionals in a clinical setting, with monitoring for infusion‑related reactions.

The most serious risks include severe myelosuppression leading to infection or bleeding, pulmonary toxicity such as interstitial pneumonitis, renal impairment, and the potential for secondary malignancies. Patients should be closely monitored for signs of infection, respiratory symptoms, and renal function changes.

Melfalan Hikma is contraindicated in patients with known hypersensitivity to melphalan or any component of the formulation, in pregnant women, and in individuals with severe renal or hepatic impairment where dose adjustment is not feasible. Caution is also advised for patients with active infections or uncontrolled cardiac disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Melphalan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT